Jason Aryeh Acquires 250 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh acquired 250 shares of Ligand Pharmaceuticals stock in a transaction on Monday, May 20th. The shares were bought at an average price of $112.01 per share, with a total value of $28,002.50. Following the completion of the transaction, the director now directly owns 59,618 shares of the company’s stock, valued at approximately $6,677,812.18. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jason Aryeh also recently made the following trade(s):

  • On Tuesday, May 14th, Jason Aryeh acquired 250 shares of Ligand Pharmaceuticals stock. The shares were bought at an average price of $112.51 per share, with a total value of $28,127.50.
  • On Wednesday, March 13th, Jason Aryeh acquired 202 shares of Ligand Pharmaceuticals stock. The shares were bought at an average price of $112.51 per share, with a total value of $22,727.02.

Shares of NASDAQ LGND traded up $1.02 during mid-day trading on Friday, reaching $113.38. The company’s stock had a trading volume of 184,947 shares, compared to its average volume of 586,427. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 18.05, a price-to-earnings-growth ratio of 2.45 and a beta of 1.33. The company has a quick ratio of 8.33, a current ratio of 8.39 and a debt-to-equity ratio of 0.57. Ligand Pharmaceuticals Inc. has a 1-year low of $98.56 and a 1-year high of $278.62.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported $1.16 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.28. The business had revenue of $43.48 million during the quarter, compared to analysts’ expectations of $38.28 million. Ligand Pharmaceuticals had a net margin of 320.12% and a return on equity of 19.21%. The company’s quarterly revenue was down 22.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.55 earnings per share. As a group, equities research analysts expect that Ligand Pharmaceuticals Inc. will post 2.34 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc lifted its position in shares of Ligand Pharmaceuticals by 3.3% during the 3rd quarter. Vanguard Group Inc now owns 2,090,137 shares of the biotechnology company’s stock worth $573,721,000 after buying an additional 66,789 shares in the last quarter. First Hawaiian Bank lifted its position in shares of Ligand Pharmaceuticals by 22.7% during the 4th quarter. First Hawaiian Bank now owns 584 shares of the biotechnology company’s stock worth $79,000 after buying an additional 108 shares in the last quarter. Virtu Financial LLC lifted its position in shares of Ligand Pharmaceuticals by 27.1% during the 4th quarter. Virtu Financial LLC now owns 1,565 shares of the biotechnology company’s stock worth $212,000 after buying an additional 334 shares in the last quarter. Boston Advisors LLC lifted its position in shares of Ligand Pharmaceuticals by 9.3% during the 4th quarter. Boston Advisors LLC now owns 5,702 shares of the biotechnology company’s stock worth $774,000 after buying an additional 485 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Ligand Pharmaceuticals by 3.4% during the 4th quarter. Bank of Montreal Can now owns 10,002 shares of the biotechnology company’s stock worth $1,357,000 after buying an additional 330 shares in the last quarter.

LGND has been the subject of a number of research analyst reports. Argus restated a “buy” rating and set a $150.00 price objective (down from $200.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, February 13th. BidaskClub upgraded shares of Ligand Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 27th. HC Wainwright restated a “buy” rating and set a $254.00 price objective (down from $281.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, March 6th. ValuEngine cut shares of Ligand Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 6th. Finally, Roth Capital reduced their price objective on shares of Ligand Pharmaceuticals from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. Ligand Pharmaceuticals currently has an average rating of “Hold” and an average price target of $206.57.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://sportsperspectives.com/2019/05/25/jason-aryeh-acquires-250-shares-of-ligand-pharmaceuticals-inc-lgnd-stock.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Featured Article: Return on Equity (ROE)

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.